EINPRESSWIRE

Neuropathic Pain Market Size Worth USD 13.28 Billion by 2032 | Rising Prevalence of Diabetic Neuropathy

Neuropathic Pain Market size was valued at USD 8.58 Billion in 2024 and the total Neuropathic Pain revenue is expected to grow at a CAGR of 5.6%



Neuropathic Pain Market

WILMINGTON, DE, UNITED STATES, November 5, 2025 /EINPresswire.com/ -- Global [Neuropathic Pain Market](https://www.maximizemarketresearch.com) was valued at USD 8.58 Billion in 2024 and is projected to reach USD 13.28 Billion by 2032, growing at a CAGR of 5.6%.

Global Neuropathic Pain Market Overview: Rising Diabetic Neuropathy, Innovative Non-Opioid Therapies, and Key Investments Driving Market Growth

Global Neuropathic Pain Market is witnessing robust growth, driven by rising prevalence of diabetic neuropathy, postherpetic neuralgia, peripheral neuropathic pain, and chronic neuropathic pain conditions. Innovations in novel analgesics, non-opioid therapies, anticonvulsants, SNRIs, targeted therapies, and neurostimulation devices, along with personalized pain management, digital pain solutions, and telemedicine adoption, are reshaping treatment strategies. Strategic investments by Pfizer, Eli Lilly, and Johnson & Johnson underscore emerging opportunities and competitive dynamics in this high-growth market.

> Rising diabetic neuropathy, postherpetic neuralgia, and advanced non-opioid therapies are driving the Neuropathic Pain Market's rapid innovation and growth globally."
>
> *Dharti Raut*

Download a Free Sample Report Today : https://www.maximizemarketresearch.com/request-sample/34992/

Rising Diabetic Neuropathy and Postherpetic Neuralgia Fuel Global Neuropathic Pain Market Growth with Innovative Therapies

Global Neuropathic Pain Market Segments Covered	
By Drug Class	Antidepressants Anticonvulsant Opioids Capsaicin Others
By Indication	Diabetic Neuropathy Spinal Stenosis Chemotherapy-Induced Peripheral Neuropathy Others
By Distribution Channel	Hospital Pharmacies Drugs Stores and Retail Pharmacies Online Pharmacies
By Region	**North America** (**United States**, Canada and Mexico) **Europe** (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russi and Rest of Europe) **Asia Pacific** (**China**, India, Japan, South Korea, Australia, ASEAN (Indonesia Malaysia, Myanmar, Philippines, Singapore, Thailand, Viet Nam etc.) and of APAC) **Middle East and Africa** (South Africa, GCC, Egypt, Nigeria and Rest of ME **South America** (Brazil, Argentina, Colombia and Rest of South America)

Global Neuropathic Pain Market is accelerating, driven by the rising prevalence of diabetic neuropathy, postherpetic neuralgia, peripheral neuropathy, and chronic neuropathic pain conditions. Innovations in novel analgesics, targeted therapies, anticonvulsants, neurostimulation techniques, and non-opioid pain management solutions, combined with an aging global population and growing healthcare awareness of pain management, are fueling robust demand and market expansion.

Challenges in Neuropathic Pain Market: Safety Concerns, Opioid Misuse, and High R&D Costs Limit Growth

Global Neuropathic Pain Market faces growth challenges due to limited efficacy of existing treatments, high R&D costs, complex regulatory approvals, and patient variability. Safety concerns, adverse effects, and opioid misuse hinder patient compliance, emphasizing the urgent need for innovative, safer, and more personalized chronic neuropathic pain management therapies.

Emerging Therapies and Digital Solutions Unlock Growth Opportunities in Global Neuropathic Pain Market

Global Neuropathic Pain Market presents significant opportunities through the development of novel analgesics, non-opioid therapies, SNRIs, anticonvulsants, and advanced neurostimulation techniques. Rising awareness among healthcare providers, adoption of digital pain management solutions, telemedicine, and personalized therapy regimens, and regional expansion in North America and Europe due to diabetic neuropathy, postherpetic neuralgia, and peripheral neuropathic pain prevalence are driving sustainable market growth.

Global Neuropathic Pain Market Segmentation: Leading Drug Classes, Key Indications, and Dominant Distribution Channels Driving Growth

Global Neuropathic Pain Market is segmented by drug class, indication, and distribution channel, with anticonvulsants leading the drug segment due to their proven efficacy in managing diabetic neuropathy, postherpetic neuralgia, and peripheral neuropathy. Hospital pharmacies dominate distribution, while diabetic neuropathy remains the top indication, driven by rising diabetes prevalence. These segments highlight lucrative opportunities for novel analgesics, non-opioid therapies, and advanced neuropathic pain treatments worldwide.

Emerging Trends in the Global Neuropathic Pain Market: Non-Opioid Therapies, Personalized Medicine, and Advanced Neurostimulation Devices

Shift Toward Non-Opioid Pain Management: Regulatory pressures and growing concerns over opioid addiction are driving adoption of safer, non-opioid therapies, including anticonvulsants, SNRIs, TCAs, and topical agents, positioning them as first-line treatments for chronic neuropathic pain worldwide.

Rise of Personalized Medicine: Global Neuropathic Pain Market is embracing tailored neuropathic pain treatment strategies based on genetic profiles and biomarker-driven insights, enabling predictive treatment response and enhancing outcomes for individual patients with diabetic neuropathy, postherpetic neuralgia, and peripheral neuropathy.

Technological Advancements in Neurostimulation Devices: Increased use of spinal cord stimulators (SCS) and TENS units offers targeted, minimally invasive, and non-pharmacological pain relief, especially for drug-resistant chronic neuropathic pain, driving innovation and expanding therapeutic options in the global neuropathic pain market.

Global Neuropathic Pain Market Updates 2024–2025: Pfizer, Eli Lilly, and J&J Drive Innovation in Non-Opioid Therapies

Pfizer Advances NGF-Targeting Therapy: In 2025, Pfizer resumed Phase 3 trials for Tanezumab, a novel neuropathic pain treatment, highlighting growing investment in non-opioid analgesics for chronic diabetic neuropathy and postherpetic neuralgia.

Eli Lilly Discontinues P2X7 Pain Candidate: On October 31 2025, Lilly halted its P2X7-inhibitor program after unmet efficacy benchmarks, signaling the challenges and high stakes in innovative neuropathic pain drug development.

Johnson & Johnson Invests in Peripheral Neuropathic Pain Solutions: In June 2024, J&J-backed Rapport Therapeutics raised $154M to advance non-opioid neuropathic pain therapies, underlining the industry shift toward safer, personalized pain management.

North America and Europe Lead Growth with Non-Opioid Therapies and Advanced Pain Management Solutions

North America Neuropathic Pain Market is witnessing robust growth, driven by the rising prevalence of diabetic neuropathy, postherpetic neuralgia, peripheral neuropathic pain, and chronic neuropathic pain conditions. Advancements in non-opioid therapies, neurostimulation techniques, targeted analgesics, and anticonvulsants, coupled with an aging population and growing healthcare awareness of pain management, are fueling demand and reshaping treatment strategies.

Europe Neuropathic Pain Market is witnessing steady growth, fueled by increasing cases of diabetic neuropathy, postherpetic neuralgia, peripheral neuropathic pain, and chronic neuropathic pain. Adoption of advanced non-opioid therapies, neurostimulation devices, SNRIs, and personalized pain management solutions, combined with an aging population and strong healthcare infrastructure, is driving innovation and expanding regional market opportunities.

Want to Preview the Full Report? Download Your Free Sample Now :
https://www.maximizemarketresearch.com/request-sample/34992/

Global Neuropathic Pain key Players:

North America:
Pfizer Inc. - New York, United States
Eli Lilly and Company - Indianapolis, United States
Johnson & Johnson - New Brunswick, United States
Teva Pharmaceutical Industries Ltd. - Tel Aviv, Israel
Purdue Pharma - Stamford, United States
Endo Pharmaceuticals Inc. - Dublin, Ireland
AbbVie Inc. - North Chicago, United States
Mallinckrodt Pharmaceuticals - Staines-upon-Thames, United Kingdom
Biogen Inc. - Cambridge, United States

Europe:
GlaxoSmithKline plc - Brentford, United Kingdom
Novartis AG - Basel, Switzerland
AstraZeneca plc - Cambridge, United Kingdom
Bayer AG - Leverkusen, Germany
Merck KGaA - Darmstadt, Germany
Boehringer Ingelheim - Ingelheim am Rhein, Germany
Sanofi - Paris, France
UCB S.A. - Brussels, Belgium
Ipsen Pharma - Paris, France
Grünenthal GmbH - Aachen, Germany

Asia Pacific:
Takeda Pharmaceutical Company Limited - Tokyo, Japan
Eisai Co., Ltd. - Tokyo, Japan
Astellas Pharma Inc. - Tokyo, Japan

Otsuka Holdings Co., Ltd. - Tokyo, Japan
Mitsubishi Tanabe Pharma Corporation - Osaka, Japan

FAQs:

What is the projected growth of the Global Neuropathic Pain Market?
Ams: Global Neuropathic Pain Market is projected to grow from USD 8.58 Billion in 2024 to USD 13.28 Billion by 2032, at a CAGR of 5.6%, driven by rising diabetic neuropathy and chronic pain conditions.

Which regions are leading the Neuropathic Pain Market?
Ans: North America and Europe lead the Neuropathic Pain Market, fueled by the prevalence of diabetic neuropathy, postherpetic neuralgia, peripheral neuropathic pain, and adoption of non-opioid therapies and advanced pain management solutions.

Who are the key players in the Global Neuropathic Pain Market?
Ans: Major companies include Pfizer, Eli Lilly, Johnson & Johnson, Teva, GlaxoSmithKline, Novartis, AstraZeneca, Takeda, and Eisai, driving innovation in non-opioid therapies, neurostimulation devices, and targeted analgesics.

Analyst Perspective:

According to industry analysts, the Neuropathic Pain Market is witnessing robust developments as leading companies like Pfizer, Eli Lilly, and Johnson & Johnson drive innovation in non-opioid therapies, neurostimulation devices, and personalized pain management. Market dynamics indicate strong competitive potential, strategic investments, and growing adoption of advanced treatments, signaling significant opportunities for stakeholders globally.

Related Reports:

Neuromyelitis Optica Spectrum Disorder Market:
https://www.maximizemarketresearch.com/market-report/neuromyelitis-optica-spectrum-disorder-market/190735/

Neurology Clinical Trials Market: https://www.maximizemarketresearch.com/market-report/neurology-clinical-trials-market/171139/

Neuroendocrine Tumor Treatment Market: https://www.maximizemarketresearch.com/market-report/global-neuroendocrine-tumor-treatment-market/110060/

About Us
Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research

initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Navale IT park Phase 3,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
+91 9607365656
sales@maximizemarketresearch.com

Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+ +91 96073 65656
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X
